| Host: |
Goat |
| Applications: |
Pep-ELISA/WB |
| Reactivity: |
Human/Mouse/Rat |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Goat polyclonal antibody anti-FRG1 (Internal) is suitable for use in ELISA and Western Blot research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA |
| Purification: |
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
| Concentration: |
0.5 mg/mL |
| Dilution Range: |
ELISA-antibody detection limit dilution 1:2000. |
| Storage Instruction: |
Store at-20°C on receipt and minimise freeze-thaw cycles. |
| Gene Symbol: |
FRG1 |
| Gene ID: |
2483 |
| Uniprot ID: |
FRG1_HUMAN |
| Immunogen Region: |
Internal |
| Accession Number: |
NP_004468.1 |
| Immunogen Sequence: |
TVTNFGEISGT |
| Function | Binds to mRNA in a sequence-independent manner. May play a role in regulation of pre-mRNA splicing or in the assembly of rRNA into ribosomal subunits. May be involved in mRNA transport. May be involved in epigenetic regulation of muscle differentiation through regulation of activity of the histone-lysine N-methyltransferase KMT5B. |
| Protein Name | Protein Frg1Fshd Region Gene 1 Protein |
| Cellular Localisation | NucleusCajal BodyNucleolusCytoplasmMyofibrilSarcomereZ LineLocalization Changes During Myogenesis From Mainly Cytoplasmic In Undifferentiated MyoblastsTo Strongly Nucleolar In Early Myotubes And Back To Cytoplasmic 5 Days Post-DifferentiationLocalized At The Z-Line In The Sarcomere Of Matured Myotubes 8 Days Post-Differentiation |
| Alternative Antibody Names | Anti-Protein Frg1 antibodyAnti-Fshd Region Gene 1 Protein antibodyAnti-FRG1 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
